Sun Pharma Share Price (SUNPHARMA)
Check the latest share price of Sun Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 11:39AM, 06 Jun 2025
NSE
Sun Pharma Stock Performance
Get live Sun Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,669Day's Price Range₹1,68952 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | -7.48 % |
| 3 Month Return | + 4.28 % |
| 1 Year Return | + 14.29 % |
| 3 Year Return | + 95.75 % |
| 5 Year Return | + 244.19 % |
| Market Stats | |
| Previous Close | ₹1,683.10 |
| Open | ₹1,669.60 |
| Volume | 8.63L |
| Upper Circuit | ₹1,851.40 |
| Lower Circuit | ₹1,514.80 |
Sun Pharma Fundamentals & Key Indicators
Check Sun Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹4,03,832.07 Cr
Return on Equity (ROE)
12.05
PE Ratio (TTM)
36.91
Return on capital employed (ROCE)
12.22
Industry PE ratio
55.94
Beta (LTM)
0.61
P/B Ratio
16.41
Dividend Yield
0.83
PEG Ratio
6.48
Quarterly Earnings Growth YOY
-18.97
EPS (TTM)
40.21
Sector
Pharmaceuticals
Book Value
265.36
Technical Analysis
Bearish
View Technical Analysis
How to invest in Sun Pharma?
Investing in Sun Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Sun Pharma or SUNPHARMA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Sun Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Sun Pharma with just a few clicks!
Sun Pharma Stock's Interest Amongst Investors
Sun Pharma Valuation
Track how Sun Pharma P/E has moved over time to understand its valuation trends.
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (36.91x)
June 5, 2025
Industry (55.94x)
June 5, 2025
Highest (184.63x)
August 28, 2020
Today’s Price to Earnings Ratio: 36.91x
Sun Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Sun Pharma.
based on 36 analysts
80.56%
Buy
11.11%
Hold
8.33%
Sell
80.56% of analysts recommend a 'BUY' rating for Sun Pharma. Average target price of ₹1981.44
Source: S&P Global Market Intelligence
Sun Pharma Share Price Target
Get share price movements and forecasts by analysts on Sun Pharma.
Sun Pharma price forecast by 36 analysts
Upside of17.73%
High
₹2450
Target
₹1981.44
Low
₹1475
Sun Pharma target price ₹1981.44, a slight upside of 17.73% compared to current price of ₹1670.2. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:29.87%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:49.89%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharma Financial Results
Get the annual and quarterly financial summary of Sun Pharma, including revenue, profit, loss and more.
Indices Featuring Sun Pharma Stock
Check stock indices that include Sun Pharma.
Sun Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Sun Pharma.
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit fell -19.01% since last year same period to ₹2,149.88Cr in the Q4 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -25.95% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.43%.
Read More about Dividends
Sun Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Sun Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 17.96% | 0.00 | |
| Mutual Funds | 12.21% | 0.00 | |
| Retail Investors | 8.87% | 0.00 | |
| Others | 6.48% | 0.00 |
Sun Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Sun Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 4,03,832.07 | 48.84% | 0.68 | NA | NA | |
| HOLD | 1,75,965.85 | 34.94% | 0.50 | NA | NA | |
| BUY | 1,06,324.63 | 33.11% | 0.67 | NA | NA | |
| BUY | 39,691.84 | -2.66% | 0.58 | NA | NA | |
| HOLD | 26,914.61 | -2.04% | 0.50 | NA | NA |
Sun Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Sun Pharma.
Sun Pharma Receives License for Psoriasis Drug - 05 Jun, 2025
SPARC has licensed its psoriasis drug, SCD-044, to Sun Pharmaceutical Industries Ltd., which is expected to share future forecasts for the drug's performance.Sun Pharma Faces Setbacks with SCD-044 and FDA Inspection - 03 Jun, 2025
Sun Pharmaceutical Industries discontinues development of SCD-044 after clinical trial failures for psoriasis and atopic dermatitis. Additionally, the Halol unit is under USFDA inspection, raising regulatory concerns. Shares fell 0.43% following the news.Sun Pharma Announces Leadership Changes and Investment Plans - 01 Jun, 2025
Sun Pharmaceutical Industries appointed Vidhi Shanghvi as a whole-time director and announced a $100 million investment to commercialise innovative products, including Unloxcyt and Leqselvi.Sun Pharma Shares Rise Amid Positive Financials - 29 May, 2025
Sun Pharmaceutical Industries shares increased by 2.03%, trading at Rs 1700.30. The company reported consistent revenue growth and improved net profit over five years, though cash flow showed fluctuations. Sentiment remains very bearish as of May 22, 2025.Sun Pharma Opens Applications for Research Fellowships - 28 May, 2025
Sun Pharma Science Foundation has opened applications for Research Fellowships aimed at recognizing excellence in original research. Indian nationals and NRI scientists are eligible, with a cash prize of Rs 5 lakh. The last date to apply is June 30.Sun Pharma Faces Pressure Amid Mixed Q4 Results - 23 May, 2025
Sun Pharmaceutical Industries announced a $25 million investment in Pharmazz Inc., raising its stake to 22.7%. However, the stock fell due to muted FY26 guidance and mixed Q4 results, with net profit declining 19% despite an 8% revenue increase. Analysts remain divided on the stock's future prospects.Sun Pharma Reports Mixed Q4 Results and Future Plans - 22 May, 2025
Sun Pharmaceutical Industries reported a 19% decline in Q4 net profit, despite 8% revenue growth. The company plans a $100 million investment in specialty products and declared a dividend of Rs 5.5 per share for FY25, pending approval. Strategic investments in dermatology and oncology were emphasized during the earnings call, with expectations for mid-to-high single-digit revenue growth in FY26.Sun Pharma Q4 Preview Shows Positive Growth Indicators - 21 May, 2025
Sun Pharmaceutical Industries is set for a strong Q4 with expected revenue growth driven by gRevlimid sales and robust domestic performance. Shares rose 1.34%, reflecting positive market sentiment.Sun Pharma's Strong Q4 Forecast and Strategic Acquisition - 20 May, 2025
Sun Pharmaceutical Industries Ltd is set to report an 18% profit increase in Q4 FY25, while Macquarie raised its target price following a successful acquisition of Checkpoint Therapeutics, enhancing its dermatology-oncology portfolio.Sun Pharma Secures FDA Approval and Acquisition Deal - 16 May, 2025
Sun Pharmaceutical Industries Limited's subsidiary Checkpoint has agreed to be acquired. Additionally, Sun Pharma received USFDA approval for a new device to treat actinic keratoses.Sun Pharma Announces Merger with Checkpoint - 14 May, 2025
Checkpoint has entered into a merger agreement with Sun Pharmaceutical Industries, valued at up to $416 million, expected to finalize in the second quarter of 2025.Sun Pharma Declines Due to US Policy Concerns - 12 May, 2025
Sun Pharmaceutical Industries Ltd experiences a significant decline, dropping for five consecutive sessions amid concerns over US drug pricing policies and tariffs. The stock has lost 7% over five sessions and is the top loser on the Nifty 50 index. Despite a surge in trading volume, the stock's performance remains weak compared to the broader market indices.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.9% return, outperforming this stock by 30.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 49.0% return, outperforming this stock by 34.7%
NEGATIVE IMPACTPrice Dip
In the last 1 month, SUNPHARMA stock has moved down by -7.5%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 14.14K Cr → 13.57K Cr (in ₹), with an average decrease of 4.0% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 3.04K Cr → 2.14K Cr (in ₹), with an average decrease of 15.2% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.92% to 8.87% in Mar 2025 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 12.24% to 12.21% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 18.05% to 17.96% in Mar 2025 quarter
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹12,815.58Cr as on March 2025 (Q4 FY25)
Net Profit: ₹2,160.64Cr as on March 2025 (Q4 FY25)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharmaceutical Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Mutual Funds that own Sun Pharma
Check out the Mutual Funds with significant holdings in Sun Pharma.
FAQs
What is Sun Pharma share price today?
Sun Pharma share price today stands at ₹1670.2, Open: ₹1669.6, Previous Close: ₹1683.1, High: ₹1689, Low: ₹1669, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
What is today's traded volume of Sun Pharma?
Today's traded volume of Sun Pharma is 8.63L. Which means that 8.63L shares of Sun Pharma were bought and sold on the stock market during today's trading session.
What is Sun Pharma's market cap today?
Today's market capitalisation of Sun Pharma is ₹4,03,832.07 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Sun Pharma?
Sun Pharma’s 52 week high is ₹1960.35 and 52 week low is ₹1377.2. The current share price of Sun Pharma is ₹1670.2, which is -14.80% down from its 52 week high and 21.28% up from its 52 week low.